Newron Shareholders Approve Board Elections at AGM 2026

Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) held on April 23, 2026. The approvals include the election of George Garibaldi and Paolo Zocchi as new, independent, and non-executive Board members. However, the motions for the extraordinary part of the meeting were not put to a vote because the required quorum was not reached.

Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected board members, anticipating their valuable contributions. He also thanked Patrick Langlois and Luca Benatti, who stepped down from the Board after many years of service, for their support of the company.

Newron Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for central and peripheral nervous system diseases. Its lead compound, evenamide, is a first-in-class glutamate modulator being developed as an add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding patients with schizophrenia. The drug is currently in the global pivotal ENIGMA-TRS Phase III development program. Clinical results have shown significant improvements in efficacy measures over time with a favorable safety profile.

Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, and with Myung In Pharm for South Korea. Its first marketed product, Xadago®/safinamide, has received marketing authorization for Parkinson's disease in multiple regions, including the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by partners Zambon, Supernus Pharmaceuticals, and Meiji Seika in various territories.

For further information, visit the company's website at www.newron.com. The original press release is available at www.newmediawire.com.